However, tirzepatide's appetite suppression often reduces overall food intake and dietary fat, paradoxically improving post-surgical diarrhea in many patients
Most patients maintained NEDA-3 status (No Evidence of Disease Activity), at approximately 59%, with a median duration of 33 months before any potential reactivation
Its also possible to feel no obvious sensation at the time of injection, apart from maybe a warmth if given IV
MYC protein stability is negatively regulated by BRD4
Min T, Bain SC (2021) The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of Type 2 diabetes: the SURPASS clinical trials
The context-dependent regulation of NRF2 creates therapeutic dilemmas: While NRF2 activation shows promise for treating neurodegenerative diseases by enhancing antioxidant defenses, its inhibition may be required in cancers where NRF2 hyperactivation promotes tumor survival and drug resistance